Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Interest Expense

Cost of servicing the company's debt during the period.

Charles River Laboratories International, Inc.NYSE: CRL

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of $30.34M rose 1.2% year over year, ahead of the -8.7% change in trailing-twelve-month interest expense. Sequentially, it rose 13.5% from the prior quarter. Over 3 fiscal years it compounded at +21.8% a year.

Context

  • Interest expense amounted to 2.7% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1.2% holds above the trailing-twelve-month pace of -8.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$30.34M+13.5% QoQ
Last fiscal yearDec 2025
$107.03M-15.3% YoY
LTMJun 2026
$106.26M-8.7% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.2%——
1 year-15.3%——
3-year CAGR+21.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
107.03M USD
Year-over-year change
-15.3%
4-year CAGR
+9.7%

Interest Expense vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 interest expense of $106.26M is the 2nd highest of the 4 companies compared; the peer median is $49.11M.
  • Its year-over-year change of -8.7% is the lowest of 3, against a peer median of +65.6%.
  • Interest expense amounts to 2.7% of revenue for CRL, versus a peer median of 2.3%.
CRL Competitors Peer median
Interest Expense for CRL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ICLRICON Public Limited CompanyLTM Jun 2026$187.13M -7.6%-6.4%2.3%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$106.26M -8.7%+21.8%2.7%
CERTCertara, Inc.LTM Mar 2026$49.11M +138.7%+3.6%11.7%
MEDPMedpace Holdings, Inc.LTM Sep 2026$0 ——0.0%
Peer median (excluding CRL) $49.11M+65.6%-1.4%2.3%

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.54B3.98B4.13B4.05B4.02B
Cost of Revenue2.21B2.51B2.63B2.72B2.79B
Gross Profit1.33B1.46B1.5B1.33B1.23B
Gross Margin37.7%36.8%36.4%32.9%30.5%
Research & Development00000
Selling, General & Admin619.92M665.1M747.86M751M743.07M
Operating Expenses744.78M811.68M885.3M1.1B717.73M
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
EBITDA820.16M986.15M1.03B581.14M410.84M
EBITDA Margin23.2%24.8%25.0%14.3%10.2%
Operating Income589.86M650.98M617.26M227.35M507.84M
Operating Margin16.7%16.4%14.9%5.6%12.6%
Interest Income652K780K5.2M8.58M4.94M
Interest Expense73.91M59.29M136.71M126.29M107.03M
Other Income / Expenses(109.15M)(27.99M)(35.98M)(134.23M)(607.34M)
Income Before Tax480.71M622.99M581.28M93.11M(99.5M)
Pre-Tax Margin13.6%15.7%14.1%2.3%-2.5%
Income Tax Expense81.87M130.38M100.91M67.82M42.66M
Net Income390.98M486.23M474.62M10.3M(144.34M)
Net Margin11.0%12.2%11.5%0.3%-3.6%
EPS (Basic)7.779.579.270.20(2.91)
EPS (Diluted)7.609.489.220.20(2.91)
Weighted Avg Shares50.29M50.81M51.23M51.38M49.56M
Weighted Avg Shares (Diluted)51.43M51.3M51.45M51.63M49.56M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.